Long-term cognitive and EEG effects of tiagabine in drug-resistant partial epilepsy

Epilepsy Research

Volumn 25, Issue 3, 1996, Pages 291-297

  Kalviainen R ^a   Aikia M ^a   Mervaala, E ^a   Saukkonen, A M ^a   Pitkanen A ^b   Riekkinen Sr , P J ^b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

cognition; EEG; epilepsy; tiagabine

Indexed keywords

ANTICONVULSIVE AGENT; TIAGABINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ELECTROENCEPHALOGRAM; FEMALE; FOCAL EPILEPSY; FOLLOW UP; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTICONVULSANTS; COGNITION; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; EPILEPSIES, PARTIAL; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NEUROTRANSMITTER UPTAKE INHIBITORS; NIPECOTIC ACIDS;

EID: 17144453671     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(96)00084-8     Document Type: Article

References (19)

1. [1] Alpherts, W.C.J. and Aldenkamp, A.P., Computerized neuropsychological assessment of cognitive functioning in children with epilepsy, Epilepsia, 31 (1990) S35-S40.
2. B receptors in excitation and inhibition of thalamocortical cells, TINS., 14 (1991) 16-21.
3. [3] Dodrill, C., Arnett, J.L., Sommerville, K. and Mengel, H., Tiagabine, Epilepsia, 36 (1995) S31.
4. [4] Dodrill, C.B., Arnett, J.L., Sommerville, K.W. and Sussman, N.M., Effects of differing dosages of vigabatrin on cognitive abilities and quality of life in epilepsy. Epilepsia, 36 (1995) 164-173.
5. [5] Dodrill, C.B., Arnett, J.L., Sommerville, K.W. and Sussman, N.M., Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy, Neurology. 43 (1993) 2501-2507.
6. [6] Engel Jr., J., A practical guide for routine EEG studies in epilepsy, J. Clin. Neurophysiol. 1 (1984) 109-142.
7. [7] Fink-Jensen, A., Suzdak, P.D., Swedberg, M.D.B., Judge, M.E., Hansen, L. and Nielsen, P.G.. The gamma-amino-butyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats, Eur. J. Pharmacol., 220 (1992) 197-201.
8. [8] Halonen, T., Nissinen, J., Jansen, J.A. and Pitkänen, A., Tiagabine prevents seizures, neuronal damage and memory in experimental status epilepticus, Eur. J. Pharmacol., 299 (1996) 69-81.
9. [9] Kälviäinen, R., Äikiä, M., Saukkonen, A.M., Mervaala, E. and Riekkinen, P.J., Vigabatrin versus carbamazepine monotherapy in newly diagnosed patients with epilepsy, a randomized controlled study. Arch. Neurol., 52 (1995) 989-996.
10. [10] Kälviäinen, R., Keränen, T. and Riekkinen, P.J., Place of newer anti-epileptic drugs in the treatment of epilepsy, Drugs, 46 (1993) 1009-1024.
11. [11] Lassen, L.C., Sommerville, K., Mengel, H.B., Edwards, D., Nielsen, B. and Shu, V., Summary of five controlled trials with tiagabine as adjuntive treatment of patients with partial seizures, Epilepsia, 36 (1995) S148.
12. [12] McGuire, A.M., Duncan, J.S. and Trimble, M.R., Effects of vigabatrin on cognitive function and mood when used as add-on therapy in patients with intractable epilepsy, Epilepsia, 33 (1992) 128-134.
13. [13] Meldrum, B.S., GABAergic mechanisms in the pathogenesis and treatment of epilepsy, Br. J. Clin. Pharmacol., 27 (1989) 3-11.
14. [14] Nielsen, E.B., Suzdak, P.D., Andersen, K.E., Knutsen, L.J.S., Sonnewald, U. and Braestrup, C., Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor, Eur. J. Pharmacol., 196 (1991) 257-266.
15. [15] Sveinbjornsdottir, S., Sander, J.W.A.S., Patsalos, P.N., Upton, D., Thompson, P.J. and Duncan, J.S., Neuropsychological effects of tiagabine, a potential new anti-epileptic drug, Seizure, 3 (1994) 29-35.
16. [16] Suzdak, P.D. and Jansen, J.A., A review of the preclinical pharmacology of tiagabine: A potent and selective anticonvulsant GABA uptake inhibitor, Epilepsia, 36 (1995) 612-626.
17. [17] Suzdak, P.D., Lack of tolerance to the anticonvulsant effects of tiagabine following chronic (21 day) treatment, Epilepsy Res., 19 (1994) 205-213.
18. [18] Walton, N.Y., Gunawan, S. and Treiman, D.M., Treatment of experimental status epilepticus with the GABA uptake inhibitor, tiagabine, Epilepsy Res., 19 (1994) 237-244.
19. [19] Wechsler, D.A., A standardized memory scale for clinical use, J. Psychol., 19 (1945) 87-95.